GlassScriptPhysician profile
Rana Mongroo
NPI 1437561461
$25,457.73
in general payments reported to CMS, 2019-2025
34 companies · $4,520 in 2025
The $4,520 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $3,247 · 2021: $3,550 · 2022: $4,346 · 2023: $4,524 · 2024: $4,326 · 2025: $4,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,082.43 |
| Education | $288.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,562.56 | 2019-2025 | Evenity, Tavneos, Prolia |
| Abbvie INC. | $3,752.61 | 2019-2025 | |
| Janssen Biotech, INC. | $3,015.85 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $1,934.86 | 2019-2024 | Taltz, Zepbound |
| Ucb, INC. | $1,787.68 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,622.56 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,429.66 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $1,355.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,224.57 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $1,142.60 | 2020-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $509.68 | 2020-2025 | Orencia |
| Radius Health, INC. | $508.72 | 2022-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $446.88 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $272.48 | 2023-2025 | Purified Cortrophin Gel |
| Bioventus LLC | $258.79 | 2020-2025 | Gelsyn-3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $237.29 | 2020-2024 | Actemra |
| Horizon Therapeutics Plc | $237.01 | 2020-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $208.62 | 2022-2025 | Strensiq |
| Genzyme Corporation | $203.75 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $152.21 | 2024-2025 | Xarelto, Tremfya |
| Fresenius Kabi USA, LLC | $130.82 | 2023-2025 | Idacio, Tyenne |
| Pacira Therapeutics, INC. | $86.20 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.57 | 2020-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $53.16 | 2020-2021 | |
| Celgene Corporation | $36.86 | 2019 | |
| Sandoz INC. | $31.02 | 2024-2025 | Jubbonti, Hyrimoz |
| Sobi, INC | $30.63 | 2020 | |
| Merck Sharp & Dohme LLC | $29.74 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $28.60 | 2019 | |
| Hikma Pharmaceuticals USA | $20.76 | 2019 | |
| Tonix Medicines, INC. | $18.54 | 2025 | Tonmya |
| Pacira Pharmaceuticals Incorporated | $16.29 | 2023 | Iovera |
| Sanofi-Aventis U.S. LLC | $14.71 | 2020 | |
| Organon LLC | $14.30 | 2023 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rana Mongroo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.